Amsterdam, The Netherlands (21 August 2017) – SMS-ONCOLOGY announces the move of its corporate office to SCHIPHOL, THE NETHERLANDS on MONDAY 21 AUGUST 2017.
This new location accommodates the strong development of the company and growing team of oncology drug development experts, and supports SMS-oncology’s mission to contribute to the development of innovative cancer therapies that will benefit patients and their families.
Located within a stone’s throw to one of Europe’s most important airports and only 10 minutes away from the city centre of Amsterdam, the new location offers a more convenient and accessible venue for visiting clients and partners, and facilitates international business travel capabilities.
Philine van den Tol, Chief Executive Officer: “I am extremely proud of how we have grown to be one of the leading oncology CROs in Europe. A great number of new, ambitious people recently joined our team in readiness for the many innovative oncology studies we are performing. Our new office substantially increases the amount of work space we have and allows us to serve our clients even better.”
Our new address
Walaardt Sacréstraat 401-403
1117 BM Schiphol
All other contact details remain the same.
About SMS-oncology: SMS-oncology is a full-service oncology CRO that in addition to clinical operations provides expert advice on oncology drug development. We perform Phase I-IV oncology studies with a specialization in the execution of early phase and immuno-oncology trials throughout Europe. Our unique competence and value proposition is providing Direction to our sponsors along the Drug-Data-Dossier path (our 4D service).